Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial

Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial

Updated Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion+ Non-Small Cell Lung Cancer

Updated Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion+ Non-Small Cell Lung Cancer

普拉替尼治疗中国RET融合阳性的局部晚期或转移性非小细胞肺癌患者的真实世界疗效及安全性研究

GEMSTONE-201: 舒格利单抗治疗复发难治性结外 NK/ T 细胞淋巴瘤(R/R ENKTL） 的多中心、单 臂 、II 期临床研究

GEMSTONE-201: pre-planned primary analysis of a multicenter, single-arm, phase 2 study of sugemalimab (suge) in patients (pts) with relapsed or refractory extranodal natural killer/T cell lymphoma (R/R ENKTL)

Sugemalimab vs placebo after concurrent or sequential chemoradiotherapy in patients with unresectabl (GEMSTONE-301): final progression-free survival analysis of a phase 3 study